GB Sciences, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Andrea Small-Howard
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3550 West Teco Avenue Las Vegas NV United States of America 89118
- IPO Date
- May 12, 2008
- CIK
- 0001165320
- Website
- gbsciences.com
- Similar Companies
- Business
- GB Sciences, Inc. (OTCQB:GBLX) is a data-driven, plant-inspired biopharmaceutical research and development company that leverages its proprietary AI-powered PhAROS™ drug discovery platform, machine learning, and high-throughput biology to develop patented, minimum essential mixtures of plant-based compounds targeting novel prescription drug treatments for multi-billion-dollar markets including Parkinson's disease, chronic pain, stress and anxiety, cytokine release syndromes, and heart failure; the platform draws from 12 global traditional medical systems to predict and validate simple formulations protected by eight issued U.S. patents and 14 global patents covering 28 unique formulas, plus 15 U.S. and 41 global patents pending on an additional 25 formulas. The company, founded in 2001 as Flagstick Venture, Inc. and renamed GB Sciences in 2016 following its evolution from Growblox Sciences, is headquartered in Las Vegas, Nevada, with a wholly-owned Canadian subsidiary, GbS Global Biopharma, Inc., and maintains a global research network encompassing nine universities, hospitals, biopharmaceutical contract manufacturing organizations, and clinical research organizations. In October 2024, GB Sciences signed an exclusive licensing agreement with EndoPure Life Sciences, LLC, granting rights to its cannabinoid-based Parkinson's disease treatment and related neurological disorder formulations for Brazil and South America in exchange for a 5% gross sales royalty and sponsorship of first-in-human clinical trials, enabling expedited regulatory pathways and post-market data to support U.S. FDA approvals.
GB Sciences (OTCMKTS:GBLX) Stock Passes Above 50 Day Moving Average – What’s Next?
Gb Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related Hyperinflammation
Gb Sciences Presenting COVID-Related Cytokine Release Syndrome Results at H.C. Wainwright's 23rd Annual Global Investment Conference
GB Sciences Is Developing Plant-Inspired Mixtures for Anxiety, Depression, and Pain From PhAROS, GB Sciences' Proprietary AI-Accelerated Drug Discovery Platform
GB Sciences Using AI Technology in Plant-Based Drug Discovery Research
GB Sciences' Board of Directors Has Passed a Unanimous Written Consent Promoting Dr. Andrea Small-Howard to the Role of President
GB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing Pharmaceuticals
GB Sciences Files Provisional Patent Application to Protect Its Proprietary Drug Discovery Platform